Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884524 | 0.86 | LTA4H (0.58) | MAOBLTA4HEPHX2BCHEFFAR1 | |
| SCHEMBL3172626 | 0.85 | LTA4H (0.70) | MAOBLTA4HEPHX2GAAMAPT | |
| SCHEMBL6505543 | 0.85 | MAOB (0.65) | MAOBLTA4HEPHX2GAAMAPT | |
| SCHEMBL3246183 | 0.85 | MAOA (0.59) | MAOASMN1; SMN2 | |
| SCHEMBL7281616 | 0.84 | LTA4H (0.68) | MAOBLTA4HEPHX2GAAMAPT | |
| Hydrochloric Acid SCHEMBL8428235 | 0.84 | MAOB (0.68) | MAOBLTA4HEPHX2GAAMAPT | |
| SCHEMBL6895507 | 0.84 | LTA4H (0.55) | LTA4HEPHX2L3MBTL1BCHEFFAR1 | |
| SCHEMBL5989617 | 0.83 | MAOB (0.58) | MAOBLTA4HEPHX2GAAMAPT | |
| SCHEMBL11129953 | 0.83 | TDP1 (0.68) | LTA4HEPHX2L3MBTL1BCHEFFAR1 | |
| SCHEMBL10795544 | 0.82 | FOXM1 (0.57) | MAOBLTA4HEPHX2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | claimed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | claimed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | claimed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | claimed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | disclosed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142277-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | MAOB 662/4885LTA4H 575/4885EPHX2 2045/4885 |
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | MAOB 662/4885LTA4H 575/4885EPHX2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.